Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Non-Hodgkin Lymphoma (Late Stage^), 2017-2021

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by CI*Rank

State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank ascending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
US (SEER+NPCR) 1 12.0 (12.0, 12.1) N/A 46,520 65.0
New Mexico 3 7.9 (7.4, 8.4) 50 (48, 50) 208 55.5
Nevada 6 8.2 (7.8, 8.7) 49 (48, 50) 295 56.6
Alabama 6 9.2 (8.8, 9.5) 48 (44, 48) 567 63.8
District of Columbia 6 9.5 (8.5, 10.6) 47 (38, 49) 64 60.5
Wyoming 6 9.6 (8.5, 10.7) 46 (37, 49) 67 60.0
Arizona 6 9.6 (9.3, 9.9) 45 (43, 48) 851 63.1
Hawaii 3 9.8 (9.2, 10.5) 44 (39, 48) 187 64.3
Mississippi 6 10.2 (9.7, 10.7) 43 (38, 47) 356 62.8
South Carolina 6 10.3 (9.9, 10.6) 42 (39, 46) 656 64.9
Tennessee 6 10.5 (10.2, 10.8) 41 (38, 45) 871 60.8
Virginia 6 10.5 (10.2, 10.8) 40 (38, 44) 1,062 64.2
Arkansas 6 10.9 (10.4, 11.4) 39 (33, 44) 407 62.9
Texas 3 11.0 (10.8, 11.1) 38 (36, 40) 3,177 62.5
Colorado 6 11.4 (11.0, 11.7) 37 (30, 39) 713 68.9
Oklahoma 6 11.4 (11.0, 11.9) 36 (28, 40) 525 65.9
Georgia 3 11.6 (11.3, 11.9) 35 (29, 37) 1,336 66.9
Maryland 6 11.8 (11.4, 12.2) 34 (24, 37) 864 67.7
Oregon 6 11.8 (11.4, 12.3) 33 (22, 37) 629 66.0
Alaska 6 11.9 (10.7, 13.1) 32 (4, 43) 85 66.4
Delaware 6 11.9 (11.0, 12.8) 31 (9, 40) 158 69.9
California 3 11.9 (11.8, 12.0) 30 (27, 35) 5,226 67.4
Florida 6 12.1 (12.0, 12.3) 29 (22, 32) 3,616 55.5
Kansas 6 12.3 (11.7, 12.8) 28 (10, 35) 425 66.4
Rhode Island 6 12.3 (11.5, 13.2) 27 (6, 38) 171 66.4
Montana 6 12.3 (11.5, 13.2) 26 (5, 38) 176 70.9
North Carolina 6 12.4 (12.1, 12.7) 25 (14, 30) 1,550 69.1
Washington 5 12.5 (12.1, 12.8) 23 (12, 31) 1,107 65.7
Vermont 6 12.5 (11.4, 13.6) 22 (3, 39) 114 67.6
Michigan 6 12.5 (12.2, 12.8) 21 (12, 30) 1,580 67.8
New Hampshire 6 12.5 (11.8, 13.3) 20 (5, 36) 231 62.5
Utah 3 12.6 (12.0, 13.2) 19 (6, 33) 362 68.2
Louisiana 3 12.6 (12.2, 13.1) 18 (8, 31) 682 66.9
Missouri 6 12.7 (12.3, 13.1) 17 (8, 29) 974 70.2
Illinois 3 12.7 (12.4, 13.0) 16 (10, 27) 1,933 67.3
Nebraska 6 12.8 (12.1, 13.5) 15 (4, 33) 291 66.0
Idaho 3 12.8 (12.1, 13.5) 14 (4, 33) 273 68.6
New York 3 12.9 (12.7, 13.1) 13 (8, 22) 3,185 63.4
New Jersey 3 12.9 (12.6, 13.2) 12 (7, 24) 1,462 62.0
Pennsylvania 6 13.1 (12.8, 13.4) 11 (5, 18) 2,241 68.2
North Dakota 6 13.2 (12.1, 14.3) 10 (1, 35) 116 68.0
South Dakota 6 13.3 (12.3, 14.3) 9 (1, 33) 143 69.2
Connecticut 3 13.4 (12.9, 13.8) 8 (3, 20) 617 65.3
Ohio 6 13.4 (13.1, 13.7) 7 (4, 13) 1,982 70.4
West Virginia 6 13.6 (12.9, 14.3) 6 (2, 21) 341 69.8
Kentucky 3 13.6 (13.2, 14.1) 5 (2, 14) 750 69.9
Maine 6 13.6 (12.9, 14.4) 4 (1, 22) 271 70.2
Minnesota 6 14.1 (13.6, 14.5) 3 (1, 8) 963 63.6
Wisconsin 6 14.2 (13.8, 14.6) 2 (1, 6) 1,057 69.8
Iowa 3 14.9 (14.3, 15.4) 1 (1, 3) 591 70.1
Indiana 6
data not available
N/A
data not available
data not available
Puerto Rico 6 5.5 (5.1, 5.8) N/A 222 39.8
Notes:
Created by statecancerprofiles.cancer.gov on 12/03/2024 12:58 am.

State Cancer Registries may provide more current or more local data.

Data cannot be shown for the following areas. For more information on what areas are suppressed or not available, please refer to the table.
Indiana, Puerto Rico

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.
Source: SEER and NPCR data. For more specific information please see the table.

Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top